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Introduction {#sec1}
============

Malaria is a devastating mosquito-borne infectious disease which caused an estimated 405,000 deaths worldwide in 2018, with 93% of the cases occurring in Africa ([@bib52]). A cycle of human malaria infection begins when an infected *Anopheles* mosquito inoculates *Plasmodium* sporozoites into the skin of a vertebrate host ([@bib3]), from where the parasites trickle into the circulation and migrate toward liver to invade hepatocytes and form exoerythrocytic forms (EEFs) enclosed within the parasitophorous vacuole. Targeting the liver stage (LS) of *Plasmodium* parasites with antimalarial drugs and vaccines is an attractive strategy to interrupt infection, as this is an obligatory and asymptomatic phase of infection that leads to the onset of symptomatic intra-erythrocytic schizogony. Furthermore, human malaria parasites, such as, *P. vivax* and *P. ovale*, produce dormant liver forms, or hypnozoites, which serve as a reservoir of infection ([@bib51]).

Discovery of novel host-parasite interactions crucial for EEF development has been severely inhibited due to lack of robust and reproducible genetically tractable malaria LS cellular models. So far, mainly human and mouse liver cancer cell lines (Huh7, HepG2, Hepa1-6), hepatic cell lines (HC04), and primary hepatocytes have been utilized for this purpose ([@bib33]). More recently, micro-patterned human hepatocyte-murine embryonic fibroblasts co-cultures (MPCCs) and *in*-*vitro*-differentiated human hepatocyte-like cells (iHLCs) were described as well ([@bib27], [@bib28]). Although cell lines are convenient to maintain and have a well-characterized genome and transcriptome, they are immortalized, and show dysregulated gene expression and abnormal signaling. For instance, hepatoma cells exhibit low abundance of drug metabolizing enzymes and transporters ([@bib13]), altered glycogen synthase kinase 3β ([@bib7]), and Toll-like receptor 3 signaling ([@bib19]), thus, displaying phenotypes not observed in primary hepatocytes. Primary hepatocytes, instead, have limited availability, short lifespan, and lose their hepatic features rapidly *in vitro*. In addition, both, primary hepatocytes and hepatoma cell lines are acquired from a small group of donors thus representing limited genetic diversity within the population. Conversely, induced pluripotent stem cells (iPSCs), can be derived from diverse human subjects thus allowing generation of customized infection models and studying donor-specific infection phenotypes or responses.

Mouse embryonic stem cells (ESCs) and human iPSCs are normal cells with virtually unlimited proliferative abilities that are highly amenable to genetic manipulation ([@bib36], [@bib40]) and share the capacity to differentiate into many different cell types ([@bib46]). In addition to self-renewal and pluripotency, large resources of stem cell lines are now available to explore mouse gene functions or investigate the impact of human genetic variation in the context of pathogen-host interactions ([@bib9], [@bib20]). These features of pluripotent stem cells (PSCs) has facilitated the development of genetically tractable PSC-based infection models for several pathogens, such as, *Plasmodium* parasites, *Salmonella typhimirium*, and hepatitis C virus ([@bib28], [@bib37], [@bib54], [@bib55]). With respect to iHLCs, liver infection models for hepatitis C virus and *Plasmodium* spp. have been reported ([@bib28], [@bib37]). For malaria specifically, iHLCs have been shown to support the development of various human and rodent *Plasmodium* spp. up to mature schizonts ([@bib28]). In addition, erythrocytes derived from mouse ESCs have also been shown to be successfully infected with *P. berghei* blood stages ([@bib55]). These developments indicate that usage of human and mouse PSCs in infectious disease research is opening up a new strategy to interrogate host-parasite interactions and can exploit existing resources, such as the Knockout Mouse Project repository. To investigate ways of leveraging this potential for research into the LS of malaria parasites, we explored both human and mouse PSC-based infection models to study *P. berghei* liver infection.

Primarily, in this study, we explored 3-methoxybenzamide (MBA)-differentiated mouse ESCs as a model to study *P. berghei* LS infection. MBA treatment of mouse ESCs presents a short, 3-day chemical differentiation method that produces large, terminally differentiated epithelial-like cells, as opposed to 25- to 35-day-long protocols for generating iHLCs. Because *P. berghei* sporozoites are highly promiscuous and can infect a variety of differentiated cell types, we hypothesized that MBA-differentiated mouse ESCs may be permissive to infection too, and could provide a new malaria LS infection model. Our results show that MBA-differentiated mouse ESCs support full development of *P. berghei* EEFs characterized by formation of large liver schizonts and release of infectious merosomes. We utilized this model to screen for host genes required for LS parasite development. In particular, we assessed the role of mouse *Pnpla2*, coding for adipose triglyceride lipase (ATGL), in *P. berghei* LS development in MBA-differentiated mouse ESCs, since preliminary small interfering RNA (siRNA) screening in Huh7 human hepatoma cells showed a negative impact on EEF development upon ATGL knockdown (see [Results](#sec2){ref-type="sec"}). In parallel, we re-examined the suitability of human PSC-derived iHLCs to study *P. berghei* LS infection *in vitro*. Our findings suggest that fully differentiated iHLCs (day 26 of differentiation) can be infected by *P. berghei* sporozoites but do not support complete development of EEFs, as depicted by the presence of small intrahepatic parasites several hours post-invasion, abnormal merozoite surface protein-1 (MSP-1) staining in liver schizonts, and lack of infectious merosomes. Overall, our results demonstrate a robust genetically modifiable mouse ESC-based *P. berghei* LS infection model which can be used to study novel and/or validate existing host-parasite interactions.

Results {#sec2}
=======

MBA-Differentiated Mouse ESCs Support Complete Development of *P. berghei* LS {#sec2.1}
-----------------------------------------------------------------------------

MBA, is an inhibitor of ADP ribosyltransferase and is known to induce differentiation in mouse ESCs within 3 days of exposure ([@bib43]). To assess the suitability of MBA-differentiated mouse ESCs as a model to study LS of *P. berghei*, we exposed two mouse ESC lines, JM8.N4 and E14, originally derived from C57Bl6/N ([@bib30]) and 129P2/OlaHsd mice ([@bib16]), respectively, to MBA. Treatment of both cell lines with MBA for 72 h resulted in a monolayer of large, flat, terminally differentiated cells ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}A). In our experience, JM8.N4 mouse ESCs show more uniform differentiation compared to E14 mouse ESCs, which still have a few colonies of undifferentiated cells left after MBA treatment.Figure 1MBA-Differentiated JM8.N4 Mouse ESCs Support Complete *P. berghei* LS Development(A) Morphology (bright-field image) of MBA- and DMSO (control)-treated JM8.N4 mouse ESCs on day 3 of differentiation.(B) A fluorescence image panel of host cell nuclei and EEFs stained with DAPI (blue) and anti-GFP Alexa Fluor 488 antibody (green), respectively. A graph of EEFs sizes in DMSO- (gray) and MBA-treated (red) JM8.N4 mouse ESCs quantified through HTS Cellomics automated microscopy. Student\'s t test was performed on mean parasite size from three independent experiments. Asterisk (^∗^) represents p value \< 0.05.(C) Bright-field and fluorescence image of merosomes released from infected MBA-treated JM8.N4 mouse ESCs beyond 60 hpi.(D) Five Theiler\'s original (TO) mice were injected per condition with cell culture supernatant from infected, MBA- and DMSO-treated (undifferentiated) JM8.N4 cells at 72 hpi.(E) MSP-1 expression in 65 hpi EEFs in MBA-differentiated JM8.N4 cells visualized by staining with mouse anti-MSP1 primary antibody and anti-mouse Alexa Fluor 555 secondary antibody (red) to visualize. DAPI (blue) and anti-GFP Alexa Fluor 488 antibody (green) staining shows nuclei and EEFs, respectively.Scale bars, 250 μm (A) and 50 μm (B, C, and E).

Upon infection with freshly isolated GFP-expressing *P. berghei* sporozoites, a range of parasite sizes were observed in both MBA-differentiated and -undifferentiated JM8.N4 and E14 cells ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}B). On average, MBA-differentiated JM8.N4 cells showed significantly larger EEFs at 48 h post-infection (hpi) and 64 hpi compared with EEFs in undifferentiated JM8.N4 mouse ESCs ([Figure 1](#fig1){ref-type="fig"}B). Similarly, MBA-differentiated E14 cells showed large EEFs at 48 hpi. However, due to the presence of several small EEFs in remaining undifferentiated colonies of cells, the average EEF size was not significantly larger than EEFs in control E14 undifferentiated cells ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Completion of LS development was marked by release of infectious merosomes from both MBA-differentiated JM8.N4 and E14 cells between 60 and 72 hpi ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}C). Only the supernatant of MBA-differentiated mouse ESCs yielded blood stage infection when injected into mice ([Figures 1](#fig1){ref-type="fig"}D and [S1](#mmc1){ref-type="supplementary-material"}D). Furthermore, immunostaining of EEFs in differentiated JM8.N4 and E14 cells with MSP-1 antibody showed MSP-1 expression around newly formed daughter nuclei in a distinct invaginating pattern ([Figures 1](#fig1){ref-type="fig"}E and [S1](#mmc1){ref-type="supplementary-material"}E), thus indicating maturation of liver schizonts. Overall, our results demonstrate that treatment with MBA is a robust differentiation protocol which renders JM8.N4 and E14 mouse ESCs fully supportive of *P. berghei* LS development.

RNA Sequencing Reveals Transcriptional Profile of MBA-Differentiated Mouse ESCs {#sec2.2}
-------------------------------------------------------------------------------

We determined the transcriptional changes induced within host cells after MBA treatment, through RNA sequencing (RNA-seq). A principal component analysis revealed no major batch effects between biological triplicates performed for each treatment, i.e., differentiated versus undifferentiated cells ([Figure 2](#fig2){ref-type="fig"}A). Differential gene expression analysis performed using Bioconductor package, DESeq, revealed 11,110 and 13,551 genes differentially expressed (DE) in MBA-differentiated JM8.N4 and E14 cells, respectively, with 9,366 DE genes common between the two cell lines. In particular, MBA-induced differentiation resulted in upregulation of smooth muscle-related genes, downregulation of pluripotency genes, and upregulation of host malaria LS-related genes in both JM8.N4 and E14 cells ([Figure 2](#fig2){ref-type="fig"}B). MBA differentiation coincided with a substantial downregulation of pluripotency markers, such as *Nanog*, *Rex2*, and *Oct3/4*. Loss of *Oct3/4* expression was confirmed through flow cytometry and microscopy in MBA-differentiated cells immunostained with anti-mouse Oct3/4 antibody ([Figure S2](#mmc1){ref-type="supplementary-material"}). Furthermore, both MBA-differentiated JM8.N4 and E14 cells showed upregulation of several smooth muscle markers, such as smooth muscle actin 2 (*Acta2*), transgelin (*Tagln*), caldesmon (*Cald1*), and calponin 1 (*Cnn1*). A previous study has also reported increased expression of these genes in mouse ESC-derived contractile smooth muscle cells ([@bib31]). Other genes, such as colony-stimulating factor 1 (*Csf-1*), filamin C gamma (*Flnc*), parvin alpha (*Parva*), cluster of differentiation 44 (*Cd44*), myosin 1C (*Myo1C*), claudin 6 (*Cldn6*), platelet/endothelial cell adhesion molecule 1 (*Pecam1*), smoothelin (*Smtn*), vinculin (*Vcl*), and calsyntenin 3 (*Clstn3*), known to be expressed in vascular smooth muscle cells ([@bib45]), were also found to be upregulated post-MBA differentiation. On comparison of transcriptome of MBA-differentiated mouse ESCs to transcriptomes of other cell types available on the MGI-Mouse Gene Expression Database (including smooth muscle cells) very low Pearson correlation values with maximum correlation (Pearson\'s r = 0.1) to trophoblast stem cell line R1AB ([Table S1](#mmc2){ref-type="supplementary-material"}) was observed. Interestingly, a previous study has reported that trophoblast progenitor cells derived from the chorion express smooth muscle actin, vimentin, and β3 tubulin ([@bib11]). In the context of LS infection, expression of typical hepatocyte markers such as albumin, tryptophan 2,3-dioxygenase, and liver fatty acid binding protein (*Lfabp*) was not identified in MBA-differentiated JM8.N4 and E14 cells, confirming the lack of characteristic hepatocyte-like features. However, host factors previously implicated in malaria LS infection, such as cluster of differentiation 81 (*Cd81*), protein kinase C zeta (*Prkcz*), and hepatocyte growth factor receptor (*Hgfr*) ([@bib6], [@bib33], [@bib42]) were upregulated in both JM8.N4 and E14 cells after MBA differentiation. Scavenger receptor class B type 1 (*Scarb1*), another host gene implicated in malaria LS infection ([@bib53]), was found to be upregulated only in MBA-differentiated E14 cells.Figure 2MBA-Differentiated Mouse ESCs Lose Expression of Pluripotency Markers and Upregulate Smooth Muscle Cell Markers(A) A principal component analysis plot showing the first (PC1) and second principal component (PC2) separating the three biological replicates of undifferentiated and MBA-differentiated, JM8.N4 and E14 mouse ESCs, into separate clusters.(B) A heatmap showing differentially expressed smooth muscle markers (red), pluripotency markers (blue), and genes previously implicated in malaria LS infection (green). Upregulation and downregulation are shown in red and blue, respectively.

A gene ontology term enrichment analysis of genes DE in MBA-differentiated mouse ESCs ([Table S2](#mmc3){ref-type="supplementary-material"}) revealed enrichment of lipid and amino acid metabolic processes, generation of precursor metabolites and energy, cytoskeleton organization, metal ion transport, Golgi vesicle transport, and pyrimidine ribonucleotide metabolic process among others. This indicates a highly metabolically active state of MBA-differentiated cells compared with their undifferentiated counterparts. Overall, our RNA-seq findings explain the conduciveness of MBA-differentiated mouse ESCs for development and maturation of *P. berghei* EEFs despite lacking typical hepatocyte features but probably sufficing the nutritional requirements of rapidly growing EEFs.

ATGL Is Dispensable for Development of *P. berghei* EEFs {#sec2.3}
--------------------------------------------------------

*Pnpla2*, or patatin-like phospholipase domain-containing protein 2, codes for a 486-amino-acid-long protein called ATGL. ATGL hydrolyses triacylglycerols (TAGs) into diacylglycerol (DAG) and free fatty acid molecules in lipid storage organelles, such as lipid droplets (LDs). Previous studies have shown that the lipidome of *P. berghei* infected Huh7 human hepatoma cells changes significantly with a major alteration in neutral lipids, such as TAG, DAG, and cholesterol esters, suggesting that host lipogenesis and lipolysis pathway are engaged during *P. berghei* LS infection ([@bib18]). Interestingly, we found a decrease in the mean fluorescence intensity (MFI) of EEFs (measured by flow cytometry) in Huh7 cells transfected with *PNPLA2*-specific siRNA as compared with control transfected cells ([Figure 3](#fig3){ref-type="fig"}A). This suggests a negative impact on the development of intrahepatic parasites when host TAG hydrolysis and fatty acid mobilization is impaired in Huh7 hepatoma cells. On the contrary, *Pnpla2-*deficient mice show accumulation of LDs in hepatocytes, however, they are fully susceptible to *P. berghei* LS infection ([@bib18]). This discrepancy in results between *PNPLA2* gene knockdown *in vitro* and gene knockout in mice (*in vivo*) could be due to off-target effects of *PNPLA2* siRNA or the inaccuracy of liver infection load assay in mice. Thus, we hypothesized that a more definitive analysis could be provided by *Pnpla2* knockout in our MBA-differentiated mouse ESCs model.Figure 3ATGL Is Dispensable for *P. berghei* EEF Development(A) Huh7 human hepatoma cells were reverse transfected with control siRNA, *PNPLA2* siRNA, or transfection reagent (no siRNA). Twenty-four hours later 50,000 freshly isolated, GFP-expressing *P. berghei* sporozoites were added to each well and MFI was quantified at 48 hpi. Error bars represent standard deviation of the mean of two independent biological replicates.(B) A schematic diagram showing biallelic targeting with CRISPR/Cas9 in mouse ESCs.(C) *Pnpla2* "critical" exon was PCR amplified from genomic DNA of wild-type and *Pnpla2*^−/−^ E14 mouse ESCs and sequenced. Cas9-damaged *Pnpla2* allele showed a 5-bp deletion compared with wild-type *Pnpla2* highlighted in black. F and R stand for forward and reverse strands, respectively.(D) *Pnpla2*^−/−^ and wild-type E14 cells fixed and stained with oil red O (ORO) and DAPI to visualize LDs and nuclei, respectively (scale bar, 100 μm). Western blot was performed on total cell lysate from *Pnpla2*^−/−^ and wild-type E14 mouse ESCs.(E) A widefield fluorescence image showing infected MBA-differentiated *Pnpla2*^−/−^ and wild-type E14 mouse ESCs stained with DAPI (blue) and anti-GFP Alexa 488 antibody (green) to visualize host cell nuclei and EEFs respectively at 48 hpi. Scale bar, 100 μm.(F) EEF size distribution quantified through HTS Cellomics automated microscopy is shown for a representative experiment (BR1) at 48 hpi. Student\'s t test was performed on mean parasite size from three independent biological replicates (n.s., not significant).(G) A bar chart showing mean and standard deviation of parasite sizes at 48 hpi in all three biological replicates, BR1, BR2 and BR3.(H) EEF size at 67 hpi quantified through HTS Cellomics automated microscopy. Mean represents average parasite size across triplicate wells from one experiment.

*Pnpla2* knockout (*Pnpla2*^−/−^) was generated in E14 mouse ESCs using a biallelic targeting strategy ([@bib5]) where sequence-specific CRISPR/Cas9 introduces a double-strand break in *Pnpla2* and deletion of the first allele occurs after integration of a drug resistance cassette from the donor vector through homologous recombination ([Figure 3](#fig3){ref-type="fig"}B). Damage in the second allele is repaired through non-homologous end-joining which is an error-prone DNA repair mechanism often leading to frameshift mutations. *Pnpla2* gene disruption was confirmed in *Pnpla2*^−/−^ E14 mouse ESCs through genotyping, which showed a 5-bp frameshift deletion in the "critical" exon ([Figure 3](#fig3){ref-type="fig"}C). Furthermore, MBA-differentiated *Pnpla2*^−/−^ E14 cells showed substantial accumulation of large LDs in their cytosol as shown by oil red O staining of neutral triglycerides, and lacked ATGL protein compared with wild-type cells ([Figure 3](#fig3){ref-type="fig"}D). The enlargement and accumulation of LDs in mutant cells is thought to occur due to accumulation of TAGs in LDs after impaired interaction of ATGL with the LDs ([@bib21]).

After confirmation of *Pnpla2* disruption and loss of ATGL protein, MBA-differentiated *Pnpla2*^−/−^ and wild-type E14 cells were infected with *P. berghei* sporozoites. At 48 hpi, the average parasite size in *Pnpla2*^*−/−*^ E14 cells was slightly lower than in wild-type cells; however, this was not statistically significant ([Figures 3](#fig3){ref-type="fig"}E--3G). The total number of EEFs was also similar in both wild-type and mutated *Pnpla2* host genetic backgrounds ([Figure S3](#mmc1){ref-type="supplementary-material"}). This suggests that sporozoite to EEF conversion is not affected in the absence of ATGL protein. To further check if the slight difference in EEF sizes observed at 48 hpi increased at later time points, parasite size was measured at 67 hpi and found to be similar in *Pnpla2*^−/−^ and wild-type E14 cells ([Figure 3](#fig3){ref-type="fig"}H). These findings clearly indicate that *Pnpla2* is dispensable and is not required for *P. berghei* LS development in MBA-differentiated cells.

NLSDM Patient Fibroblasts Are Permissive to *P. berghei* Infection and Growth {#sec2.4}
-----------------------------------------------------------------------------

Mutations in human *PNPLA2* gene causes neutral lipid storage disease with myopathy (NLSDM) characterized by severe accumulation of TAGs in cytoplasmic LDs in neutrophils, liver, muscle, and heart ([@bib21], [@bib38]). To test if natural genetic variation in *PNPLA2* affects susceptibility to malaria LS infection, we obtained two NLSDM patient dermal fibroblast lines F121-12N-YC280270 and F122-12N-LB141159 carrying mutation in exon 5 (613dupC) and exon 8 (1051delC), respectively ([@bib35]). Two healthy dermal fibroblast lines, F011-11N-RM01/02 and F097-12N-BH-01/02, were also received from the same source to be used as healthy controls in sporozoite infection assays. NLSDM patient fibroblasts showed accumulation of LDs in the cytosol and lacked ATGL protein when compared with healthy fibroblasts ([Figures 4](#fig4){ref-type="fig"}A and 4B). To check if LS phenotype observed in *Pnpla2*^−/−^ E14 mouse ESCs could be reproduced in NLSDM fibroblasts, patient and healthy fibroblasts were infected with GFP-expressing *P. berghei* sporozoites in parallel. Both healthy and patient fibroblasts showed comparable infection rates at 48 hpi ([Figure 4](#fig4){ref-type="fig"}C). Furthermore, patient fibroblast line labeled "Diseased 1" showed slightly higher MFI than the two healthy control fibroblast lines. However, the MFI of second patient fibroblast line labeled "Diseased 2" was comparable with healthy fibroblasts ([Figure 4](#fig4){ref-type="fig"}D). These results were validated through confocal microscopy where EEFs in patient and healthy fibroblasts looked comparable in size at 48 hpi ([Figure 4](#fig4){ref-type="fig"}E).Figure 4NLSDM Patient Fibroblasts with Point Mutations in *PNPLA2* Do Not Prevent *P. berghei* Infection and Growth(A) A bright-field image of ORO staining of lipid droplets (white arrows) in healthy (control) and patient (diseased) fibroblasts. Scale bar, 2 μm.(B) Western blot on total cell lysate from healthy and patient fibroblasts stained with rabbit anti-ATGL/PNPLA2 antibody (1:600) shows absence of PNPLA2 protein (\~55 kDa) in patient fibroblasts. Anti-tubulin staining was performed as a loading control.(C and D) (C) Infection rate and (D) MFI for *P. berghei*-infected diseased and control fibroblasts quantified by flow cytometry at 48 hpi. Error bars represent mean ± standard deviation of triplicates. Data shown are from a representative experiment out of two biological replicates.(E) A representative confocal microscopy image showing *P. berghei* EEFs stained with anti-GFP Alexa Fluor 488 antibody in diseased and control fibroblasts at 48 hpi. Host cell nuclei were stained with DAPI. Scale bar, 20 μm.

It is clearly evident from these results that both patient and healthy fibroblast lines show variation in infection rate and/or MFI value between themselves. This could be due to difference in their genetic background. To avoid being confounded by difference in host genetic backgrounds contributing to variation in infection and parasite development between fibroblast lines, *PNPLA2* knockdown was performed in healthy fibroblast line F011-11N-RM-01/02 (Control 1) and infected with *P. berghei* sporozoites to determine the role of *PNPLA2* during LS infection ([Figure S4](#mmc1){ref-type="supplementary-material"}). *PNPLA2* transcript knockdown measured by qRT-PCR showed only 16% of transcript remaining in healthy fibroblasts at 48 h post-transfection (i.e., 84% transcript knockdown) compared with control siRNA transfected fibroblasts ([Figure S4](#mmc1){ref-type="supplementary-material"}A). *P. berghei* infection rate and MFI in *PNPLA2* siRNA transfected fibroblasts was not significantly different from control transfected cells ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C). This confirms that the reduced EEF development observed in *PNPLA2* knockdown Huh7 hepatoma cells ([Figure 3](#fig3){ref-type="fig"}A) could not be reproduced, both, in MBA-differentiated *Pnpla2*^−/−^ E14 mouse ESCs, and, NLSDM patient fibroblasts. Thus, PNPLA2 protein is dispensable for *P. berghei* LS infection in both, differentiated mouse ESCs, and, human fibroblasts. Overall, these results highlight the utility of MBA-differentiated mouse ESCs to validate the role of candidate host genes previously identified through gene knockdown approaches which may have frequent off-target hits leading to false positives.

iHLCs Do Not Support Complete Development and Maturation of *P. berghei* EEFs {#sec2.5}
-----------------------------------------------------------------------------

The use of NLSDM fibroblasts above illustrates the potential of exploiting genetic variation in primary cells from different human donors to understand host-pathogen interactions. Dozens of candidate loci in the human genome have been linked to severe malaria in humans through genome wide association studies ([@bib26], [@bib49]). Libraries of human iPSCs are now becoming available that reflect much of the most abundant variation in the human genome ([@bib1], [@bib44]). We, therefore, tested if human ESC- or iPSC-derived hepatocyte-like cells can be used as a model to study *Plasmodium* LS infection. In this study, we utilized iHLCs derived through a 25- to 35-day-long differentiation of human ESCs or iPSCs into definitive endoderm cells, which gave rise to hepatic progenitors eventually maturing into hepatocytes ([@bib14]). iHLCs generated by this protocol have been characterized previously and display hepatic characteristics, such as expression of albumin, alpha fetal protein, glycogen storage, and cytochrome activity from day 20 onward. Basic hepatic metabolic functions start to appear from day 25 onward with increasing maturation up to day 35 ([@bib50]). The number of days required for hepatoblast maturation into iHLCs may vary between different cell lines and needs to be optimized in each case ([@bib14]).

In this study, we derived wild-type A1ATcorr iHLCs from A1ATcorr hiPSCs ([@bib57]) and observed for any morphological and phenotypic traits similar to primary hepatocytes. A1ATcorr iHLCs show a typical hepatocyte-like polygonal morphology with binucleate cells ([Figure 5](#fig5){ref-type="fig"}A) and express hepatocyte nuclear factor 4α (HNF4α) ([Figure 5](#fig5){ref-type="fig"}B), which is a transcription factor required for maintaining hepatic gene expression, bile acids secretion and lipid (e.g., triglycerides and cholesterol) homeostasis in hepatocytes ([@bib15]). HNF4α has been shown expressed in nascent hepatic cells, hepatoblasts and differentiated hepatocytes, thus marking liver-specific differentiation ([@bib41]). Heterogeneous expression of HNF4α in the nuclei of A1ATcorr iHLCs reflects varied extent of differentiation of each cell. This is corroborated by previous studies which have shown that only 60% of iHLCs show HNF4 α expression and 80% show albumin expression which is another marker of hepatocyte differentiation ([@bib41], [@bib50]). No HNF4α expression was detected in undifferentiated A1ATcorr hiPSCs nuclei (negative control) ([Figure 5](#fig5){ref-type="fig"}B). Having confirmed the hepatocyte-like features of iHLCs, we systematically studied *P. berghei* infection, growth and maturation in them. As shown in [Figure 5](#fig5){ref-type="fig"}C, the infection rate (percentage of infected host cells) in A1ATcorr iHLCs infected with *P. berghei* sporozoites was about 0.21%, which was significantly lower compared with 0.53% in Huh7 human hepatoma cells (used as a comparator) at 48 hpi. Further development of *P. berghei* EEFs at 48 hpi was assessed by measuring parasite size using automated imaging. Although multiple parasite daughter nuclei were observed in both cell types, the average parasite size in A1ATcorr iHLCs was about 136.13 μm^2^ compared with slightly higher 156.30 μm^2^ in Huh7 cells ([Figure 5](#fig5){ref-type="fig"}D). A frequency distribution of EEF size in A1ATcorr iHLCs was similar to Huh7 cells except that fewer large EEFs between 300 and 600 μm^2^ were present in iHLCs at 48 hpi ([Figure 5](#fig5){ref-type="fig"}E). Finally, the maturation of EEFs in A1ATcorr iHLCs was studied by staining infected cells with anti-MSP-1 antibody. MSP-1 is expressed in the plasma membrane of late liver schizonts and marks late LS maturation ([@bib47]). The pattern of MSP-1 staining in parasite plasma membrane indicates the extent of EEF maturation and membrane invagination around newly formed daughter nuclei ([@bib12]). EEFs in A1ATcorr iHLCs showed abnormal pattern of MSP-1 staining at 65 hpi, lacking segregation of newly formed daughter nuclei into distinct units ([Figure 5](#fig5){ref-type="fig"}F). This is characteristic of delay in maturation of EEFs. In contrast, Huh7 EEFs showed a typical grape-like pattern of MSP-1 staining around individual daughter parasites ([Figure 5](#fig5){ref-type="fig"}F). Keeping infected cultures beyond 65 hpi (up to 96 hpi) resulted in occasional release of few merosome-like structures from A1ATcorr iHLCs but these did not produce blood stage infection in Theiler\'s original (TO) mice upon intravenous injection. On the contrary, merosomes released from infected Huh7 cells (control) always produced a positive blood stage infection in mice ([Figure 5](#fig5){ref-type="fig"}G). Overall, these results suggest that A1ATcorr iHLCs are susceptible to *P. berghei* infection but EEFs do not attain complete maturation in them. To rule out inappropriate host genetic background as a possible cause of stunted parasite growth, iHLCs derived from H9 human ESCs ([@bib48]) and BBHX8 human iPSCs ([@bib34]) were infected with *P. berghei* sporozoites. None of the two genetic backgrounds supported complete maturation of *P. berghei* EEFs as well ([Figure S5](#mmc1){ref-type="supplementary-material"}). In conclusion, our results show that iHLCs are a sub-optimal model to study LS of *P. berghei* parasites.Figure 5iHLCs Do Not Support Complete Development of *P. berghei* EEFs(A) A bright-field image of iHLCs showing polygonal, binucleate (white arrows) hepatocyte-like morphology.(B) HNF4α expression in iHLCs and undifferentiated hiPSCs visualized by staining with goat anti-HNF4α primary antibody and anti-goat Alexa Fluor 596 secondary antibody (purple). Host cells were stained with DAPI (blue). Images are representative of more than three independent differentiations.(C) Infection rate in A1ATcorr iHLCs and Huh7 cells at 48 hpi quantified by flow cytometry. Data represent mean ± standard error of the mean of three independent experiments. Student\'s t test was performed on mean of technical replicates from three independent experiments. p value \< 0.05 shown as asterisk (^∗^).(D) EEF size in A1ATcorr iHLCs and Huh7 cells at 48 hpi. Mann-Whitney test was applied to test for statistically significant difference. Data represented from triplicate wells of a representative experiment. n.s., not.(E) A frequency distribution (as percentage) of EEF sizes in A1ATcorr iHLCs and Huh7 cells at 48 hpi.(F) A representative confocal image of GFP-expressing EEFs in A1ATcorr iHLCs and Huh7 cells stained with anti-MSP-1 antibody (red) and DAPI (blue) at 65 hpi.(G) Merosome-like structures released at 72 hpi from infected A1ATcorr iHLCs and Huh7 cells were injected intravenously into TO mice from two independent experiments. Combined data are shown from both experiments.Scale bars, 100 μm (A and B) and 20 μm (F).

Discussion {#sec3}
==========

We have shown that differentiation with MBA dramatically increases permissiveness of JM8.N4 and E14 mouse ESCs to *P. berghei* sporozoite infection in contrast to undifferentiated cells. Transcriptional profiling post-MBA differentiation revealed increase in expression of several smooth muscle-related genes but lack of typical hepatocyte markers. Nonetheless, complete development of *P. berghei* EEFs in this model may be attributable to the expression of *Scarb1*, *Met*, *Cd81*, *Hgfr*, and *Prkcz*; host genes previously implicated in malaria LS infection. In addition, significant enrichment of lipid, amino acids, and ribonucleotide metabolic processes along with vesical transport pathways may indicate nutritionally rich and metabolically active host cell environment post-MBA differentiation. We have clearly demonstrated the utility of this infection model to validate LS phenotypes previously associated with candidate host genes identified in gene knockdown studies. In particular, we established that host *Pnpla2* involved in neutral lipid mobilization is dispensable for *P. berghei* LS infection in MBA-differentiated mouse ESCs. We corroborate this finding by showing that there is no significant difference in *P. berghei* LS infection between NLSDM patient fibroblasts and healthy fibroblasts.

*Plasmodium* parasites can synthesize fatty acids using the type II fatty acid synthesis (FAS II) pathway. This may possibly explain why lack of *Pnpla2* which hydrolyses TAGs to release fatty acids and DAGs does not impact growth of *P. berghei* EEFs. Another possibility could be involvement of redundant genes/pathways which may become a substitute for ATGL in *Pnpla2* knockout cells. Discrepancy in infection phenotype between *PNPLA2* siRNA knockdown and *Pnpla2* gene knockout could be due to off-target effects of siRNAs leading to false positive hits thus requiring validation in a gene knockout system. The widely used CRISPR/Cas9 system can introduce precise mutations in any genomic loci with minimal off-target effects to mutate or correct gene/s of interest in diverse mammalian cell lines, including stem cells ([@bib8], [@bib10]). This outlines a major advantage of developing stem cell-based malaria LS infection model. Overall, our results are a proof-of-principle that MBA-differentiated mouse ESCs can be used for future gene-infection phenotype validation studies along with identification of new host-parasite interactions occurring during malaria LS infection.

Next, we tested if a hESC- or hiPSC-based malaria LS infection model can be developed as this would allow us to recapitulate human genetic variation occurring in primary cells of donors and study its effect on malaria LS infection. We showed that iHLCs derived from hiPSCs (A1ATcorr and BBHX8) or hESCs (H9) can be infected with *P. berghei* sporozoites, but do not support functional maturation of EEFs into segmented liver schizonts and infectious merosomes. This could be due to lack of one or more host factors in iHLCs known to affect growth and maturation of *Plasmodium* LS. Some of the host factors known to affect invasion and EEF development include, L-FABP which is possibly involved in delivering fatty acids to parasitophorous vacuole via interaction with PVM protein UIS3 ([@bib22]), SRB1 which plays a role in *Plasmodium* sporozoite entry and possibly supplies cholesterol required for EEF growth ([@bib53]), and host kinases PKCzeta whose knockdown leads to reduced parasite load *in vitro* and *in vivo* ([@bib32]). In addition, host metabolism, immunity, apoptosis and ER stress-related pathways have also been previously implicated in parasite growth and survival ([@bib2]). Furthermore, incomplete EEF development in iHLCs could be due to acquisition of anti-parasitic factors or immune-competency during maturation into hepatocyte-like cells. Previous studies have shown that cell-autonomous host defense mechanisms, such as interferon induced reactive oxygen and nitrogen species, immunity-related GTPases mediated disruption of parasitophorous vacuole, autophagy, and nutrient restriction, are major strategies used by a diverse range of primary cells to target intracellular protozoa such as *Leishmania*, *Toxoplasma*, *Plasmodium*, and *M. tuberculosis* ([@bib24], [@bib25]). In context with *P. berghei* LS infection, [@bib23] showed that *Plasmodium* RNA is recognized by pattern recognition receptor in infected hepatocytes which induces a type I interferon response responsible for recruiting liver leukocytes to eliminate intracellular EEFs. In contrast, undifferentiated mouse ESCs are known to lack strong immunological response when infected with bacterial pathogens such as *Salmonella* and *Shigella in vitro* ([@bib56]). This could possibly mean that as ESCs differentiate into primary hepatocytes they gain host defense factors required for targeting intracellular pathogens. In fact, Ng et al*.* show that hepatoblasts are more permissive to *P. falciparum* infection than developmentally mature iHLCs.

While our study shows that iHLCs are a sub-optimal model to study LS infection, a previous study demonstrated that *P. falciparum*, *P. vivax*, *P. yoelii*, and *P. berghei* EEFs can mature in stem cell-derived hepatocytes ([@bib28]). The discrepancy between our results could be due to use of different human PSC lines in the two studies, which may present variably suitable host genetic background to support infection and/or to form fully mature hepatocyte-like cells. Ng et al. reported formation of large, multinuclear, MSP-1 expressing liver schizonts in iHLCs, however, release of infectious merosomes from the host cell has not been addressed. In our opinion, one of the major challenges which remains to be tackled to develop successful stem cell-based LS models is to further improve hepatocyte differentiation protocols to generate fully mature, adult primary hepatocyte-like cells from diverse human stem cell lines instead of featuring fetal hepatocyte characteristics ([@bib4]). Molecules such as cyclic AMP and other small molecules have been shown to increase maturation of iHLCs ([@bib29], [@bib39]) and may facilitate development of better iHLC-based models in future. In addition, it is possible that essential nutrients such as D-glucose may have limited availability to EEFs in iHLCs. Previous research has shown that a minimum of 2,000 mg/L/day of D-glucose is essential for LS maturation ([@bib17]). Thus, in future, efforts can be focused on optimizing iHLC media composition and culture conditions to promote complete LS maturation.

Overall, this study assessed the suitability of both, mouse and human PSC-based *P. berghei* LS infection models. iHLCs prove to be a sub-optimal infection model, however, MBA-differentiated mouse ESCs should enable the validation and discovery of new host-parasite interactions which are essential for *P. berghei* intrahepatic development and can be targeted to devise novel therapeutic interventions to treat malaria.
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Resource Availability {#sec4.1}
---------------------

The accession number for the RNA sequencing data reported in this paper is European Nucleotide Archive: [ERP121187](https://www.ebi.ac.uk/ena/data/search?query=ERP121187){#interref0010}.

Cell Lines, Parasite Lines, and Sporozoite Infection Assay {#sec4.2}
----------------------------------------------------------

JM8.N4, E14, Huh7, and fibroblasts were maintained in their respective media at 37°C in 5% CO~2~. Human iPSCs and ESCs were maintained in a chemically defined medium and differentiated into iHLCs using a previously published protocol ([@bib14]). PbGFPcon parasite line was used for all sporozoite infections. Full details on media composition and infection assay are provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

MBA Differentiation of Mouse ESCs {#sec4.3}
---------------------------------

E14 and JM8.N4 mouse ESCs were differentiated using 9 mM and 7 mM MBA treatment, respectively, for 3 days. Full details are provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.
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